VELA Investment Management LLC Has $6.85 Million Stake in Johnson & Johnson $JNJ

Key Points

• VELA Investment Management LLC increased its stake in Johnson & Johnson by 18.6% in Q4 to 33,116 shares, worth about $6.85 million, making JNJ its 9th-largest holding (1.6% of the portfolio).
• Johnson & Johnson beat Q1 estimates with EPS $2.70 (vs. $2.68) and revenue of $24.06 billion (up 9.9% YoY), and set FY2026 guidance at $11.45–$11.65 EPS (consensus ~11.57).
• The company raised its quarterly dividend to $1.34 (annualized $5.36, yield ~2.4%), institutional investors own about 69.55% of shares, and analysts have a consensus "Moderate Buy" target of $252.48.

VELA Investment Management LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 18.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 33,116 shares of the company's stock after acquiring an additional 5,183 shares during the period. Johnson & Johnson comprises 1.6% of VELA Investment Management LLC's portfolio, making the stock its 9th biggest position. VELA Investment Management LLC's holdings in Johnson & Johnson were worth $6,853,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Johnson & Johnson by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock valued at $49,740,362,000 after acquiring an additional 3,731,074 shares during the period. Wellington Management Group LLP grew its stake in Johnson & Johnson by 3.8% during the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock worth $4,789,914,000 after buying an additional 956,239 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Johnson & Johnson by 3.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company's stock worth $4,568,313,000 after buying an additional 835,146 shares during the last quarter. Legal & General Group Plc grew its stake in Johnson & Johnson by 2.8% during the 3rd quarter. Legal & General Group Plc now owns 19,450,064 shares of the company's stock worth $3,606,431,000 after buying an additional 532,790 shares during the last quarter. Finally, Amundi grew its stake in Johnson & Johnson by 19.3% during the 3rd quarter. Amundi now owns 13,354,936 shares of the company's stock worth $2,512,719,000 after buying an additional 2,163,838 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.6%

Shares of JNJ stock opened at $225.59 on Wednesday. The stock has a 50 day moving average of $238.49 and a 200 day moving average of $220.15. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a market cap of $543.05 billion, a P/E ratio of 26.08, a P/E/G ratio of 2.20 and a beta of 0.27. Johnson & Johnson has a twelve month low of $146.12 and a twelve month high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson's quarterly revenue was up 9.9% on a year-over-year basis. During the same period last year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, May 26th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson's payout ratio is currently 60.12%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president owned 26,769 shares of the company's stock, valued at $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 30,142 shares of company stock valued at $7,360,528 in the last three months. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. Stifel Nicolaus boosted their price target on Johnson & Johnson from $220.00 to $250.00 and gave the company a "hold" rating in a research note on Wednesday, April 15th. TD Cowen initiated coverage on Johnson & Johnson in a research note on Wednesday, April 8th. They set a "buy" rating and a $250.00 price target on the stock. Scotiabank reiterated an "outperform" rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Morgan Stanley set a $283.00 price target on Johnson & Johnson in a research note on Wednesday, April 15th. Finally, The Goldman Sachs Group boosted their price objective on Johnson & Johnson from $265.00 to $275.00 and gave the company a "buy" rating in a report on Wednesday, April 15th. Eighteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $252.48.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.